Retatrutide
Lilly’s investigational GIP, GLP-1 and glucagon receptor triple agonist: trial results, dosing studied, side effects and regulatory status.
All Retatrutide coverage
Articles on this compound are in medical review.
The Weekly Peptide Brief
FDA updates and new research, explained in 5 minutes. Every week, free.
Free. Unsubscribe anytime. We never sell your email.